Core Viewpoint - The company's stock price fluctuations are influenced by a combination of market sentiment, industry dynamics, and macroeconomic factors [1] Group 1 - The company stated that its performance data will be included in the 2025 annual report [1] - The 2025 annual report is scheduled to be disclosed on March 25, 2026, at which point specific performance details will be provided [1]

Core Viewpoint - The company is facing unusual losses in the fourth quarter and has been questioned by investors regarding its financial performance and future disclosures [2] Group 1: Financial Performance - The company has received inquiries about the unusual losses reported in the fourth quarter [2] - The company will disclose its annual report for 2025 on March 25, 2026, which will include detailed performance data [2] Group 2: Compliance and Information Disclosure - The company emphasizes its commitment to strict adherence to information disclosure principles to ensure fair access to information for investors [2]

Core Viewpoint - As of January 20, 2026, the number of shareholders for Furuimei Medical (300049) is reported to be 22,242 [1] Company Information - Furuimei Medical has engaged with investors through an interactive platform, indicating a level of transparency and communication with its shareholder base [1] - The company is actively monitoring its shareholder count, which may reflect its growth and investor interest [1]

Group 1 - The core viewpoint of the article highlights that Furui Medical (300049) has released its earnings forecast for 2025, projecting a significant increase in net profit [1][3] - On January 23, 2026, Furui Medical's stock closed at 73.2 yuan, with a slight increase of 0.87% and a trading volume of 65,000 shares, amounting to a transaction value of 479 million yuan [1] - The company anticipates a net profit attributable to shareholders ranging from 135 million yuan to 164 million yuan for 2025, representing a year-on-year growth of 19.17% to 44.77% [1][3] Group 2 - The earnings forecast indicates that the net profit after deducting non-recurring gains and losses is expected to be between 127 million yuan and 166 million yuan, reflecting a growth of 7.89% to 41.02% year-on-year [1] - The growth in earnings is primarily driven by the increase in revenue and profit from the medical device business of its French subsidiary, along with stable contributions from the company's managed medical strategy in pharmaceuticals and medical services [1][3] - The net inflow of main funds on January 23 was 4.0411 million yuan, while retail investors experienced a net outflow of 7.9863 million yuan [1][3]

Core Viewpoint - Furui Medical Technology Co., Ltd. (福瑞医科) is expected to report a significant increase in net profit for the fiscal year 2025, driven by growth in its medical device business and stable contributions from its managed healthcare strategy [1] Financial Performance - The company's stock closed at 73.2 yuan on January 23, 2026, up 0.87% from the previous trading day, with a total market capitalization of 19.396 billion yuan [1] - The expected net profit attributable to shareholders for 2025 is projected to be between 135 million yuan and 164 million yuan, representing a year-on-year growth of 19.17% to 44.77% [1] - The net profit after deducting non-recurring gains and losses is anticipated to be between 127 million yuan and 166 million yuan, indicating a year-on-year increase of 7.89% to 41.02% [1] Business Drivers - The growth in net profit is primarily attributed to the increase in revenue and profit from the company's French subsidiary's medical device business [1] - The stable contributions from the company's managed healthcare strategy, including pharmaceuticals and medical services, also play a significant role in the expected performance [1] - Non-recurring gains and losses are expected to have a minimal impact on the net profit [1]

Core Viewpoint - The company, Furu Medical (300049.SZ), projects a net profit attributable to shareholders of 135 million to 164 million yuan for 2025, reflecting a year-on-year change of 19.17% to 44.77% [1] Group 1: Financial Projections - For 2025, the medical device business of the French subsidiary is expected to achieve revenue of approximately 1.05 billion to 1.2 billion yuan, with a year-on-year growth of about 13.77% to 30.02% [1] - The net profit from the medical device business is projected to be around 220 million to 260 million yuan, representing a year-on-year increase of approximately 15.48% to 36.47% [1] - The net profit attributable to shareholders from the medical device business is estimated to be about 110 million to 130 million yuan, showing a year-on-year growth of approximately 15.27% to 36.23% [1] Group 2: Other Business Segments - The company plans to adhere to a managed care strategy, with revenue from pharmaceuticals, medical services, and other businesses expected to be around 450 million to 480 million yuan, leading to a net profit attributable to shareholders of approximately 25 million to 34 million yuan [1] - The impact of non-recurring gains and losses on net profit is anticipated to be in the range of -2 million to -8 million yuan for 2025 [1]

Core Viewpoint - Furuike Medical (300049.SZ) has disclosed its performance forecast for 2025, expecting a net profit attributable to shareholders of between 135 million to 164 million yuan, representing a year-on-year growth of 19.17% to 44.77% [1] Financial Performance - The company anticipates a net profit after deducting non-recurring gains and losses to be between 127 million to 166 million yuan, indicating a year-on-year increase of 7.89% to 41.02% [1]

Core Viewpoint - The company, Furuimei Medical, forecasts a significant increase in net profit for the year 2025, indicating strong growth prospects driven by its medical device business and strategic management initiatives [1] Group 1: Financial Performance Forecast - The company expects a net profit attributable to shareholders for 2025 to be between 135 million and 164 million yuan, representing a year-on-year increase of 19.17% to 44.77% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 127 million and 166 million yuan, with a year-on-year growth of 7.89% to 41.02% [1] Group 2: Business Segment Performance - The medical device business of the French subsidiary is anticipated to generate revenue of approximately 1.05 billion to 1.2 billion yuan in 2025, reflecting a year-on-year growth of about 13.77% to 30.02% [1] - The net profit from the medical device segment is expected to be around 220 million to 260 million yuan, with a year-on-year increase of approximately 15.48% to 36.47% [1] - The net profit attributable to shareholders from this segment is projected to be between 110 million and 130 million yuan, showing a year-on-year growth of about 15.27% to 36.23% [1] Group 3: Strategic Initiatives - The company will continue to implement a managed care strategy, with revenue from pharmaceuticals, medical services, and other businesses expected to be between 45 million and 48 million yuan [1] - The net profit attributable to shareholders from these segments is forecasted to be between 2.5 million and 3.4 million yuan [1] - The impact of non-recurring gains and losses on net profit is estimated to be between -2 million and -8 million yuan [1]

Financial Projections - The estimated net profit attributable to shareholders for 2025 is projected to be between 135 million and 164 million CNY, representing a year-on-year increase of 19.17% to 44.77% compared to 113.29 million CNY in 2024[3] - The estimated net profit after deducting non-recurring gains and losses is expected to be between 127 million and 166 million CNY, reflecting a year-on-year growth of 7.89% to 41.02% from 117.72 million CNY in the previous year[3] - The net profit from the French subsidiary's medical device business is expected to be between 220 million and 260 million CNY, indicating a year-on-year increase of 15.48% to 36.47%[5] - The company aims to achieve revenue of approximately 450 million to 480 million CNY from its managed medical services and other businesses, with an estimated net profit attributable to shareholders of about 25 million to 34 million CNY[5] - The impact of non-recurring gains and losses on net profit is estimated to be between -2 million and -8 million CNY for the year 2025[5] Revenue Expectations - The medical device business of the French subsidiary is anticipated to generate revenue of approximately 1.05 billion to 1.20 billion CNY, with a year-on-year growth of about 13.77% to 30.02%[5] Performance Forecast - The performance forecast is based on preliminary calculations by the company's finance department and has not been audited[6] - The company has communicated with the auditing firm regarding the performance forecast, and there are no significant disagreements[4] - Investors are advised to make cautious decisions and be aware of investment risks as the financial data will be finalized in the 2025 annual report[7] - The performance forecast period is from January 1, 2025, to December 31, 2025[3]

Group 1 - The core point of the article is that Furuimei (300049) has removed its "Love Liver for Life" app and migrated its related functions to the company's internet hospital [1] Group 2 - The company responded to investor inquiries on its interactive platform regarding the app's status [1]